About Tango Therapeutics
Tango Therapeutics is a company based in Cambridge (United States) founded in 2017. Tango Therapeutics has raised $165 million across 5 funding rounds from investors including Gilead, Casdin Capital and Boxer Capital. The company has 155 employees as of December 31, 2024. Tango Therapeutics offers products and services including PRMT5 Program and CoREST Program. Tango Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Metabolon and MiRagen, among others.
- Headquarter Cambridge, United States
- Employees 155 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Tango Therapeutics, Inc.
-
Annual Revenue
$42.07 M (USD)15.17as on Dec 31, 2024
-
Net Profit
-$130.3 M (USD)-28.07as on Dec 31, 2024
-
EBITDA
-$143.1 M (USD)-28.04as on Dec 31, 2024
-
Total Equity Funding
$165 M (USD)
in 5 rounds
-
Latest Funding Round
$15 M (USD), Post-IPO
Oct 24, 2025
-
Investors
Gilead
& 4 more
-
Employee Count
155
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Tango Therapeutics
Tango Therapeutics is a publicly listed company on the NASDAQ with ticker symbol TNGX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Tango Therapeutics
Tango Therapeutics offers a comprehensive portfolio of products and services, including PRMT5 Program and CoREST Program.
Targets tumors using synthetic lethality for precision medicine.
Develops targeted therapies for cancer treatment approaches.
People of Tango Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
43 people
Senior Team
9 people
Product Management Team
7 people
Software Development Team
6 people
Scientist Team
6 people
Scientific Team
5 people
Finance and Accounting
4 people
Human Resources and Administration
4 people
Unlock access to complete
Funding Insights of Tango Therapeutics
Tango Therapeutics has successfully raised a total of $165M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $15 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Tango Therapeutics
Tango Therapeutics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Gilead, Casdin Capital and Boxer Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked | |
|
Biotech startups are funded by this venture capital firm.
|
Locked | Locked | Locked | |
|
Tavistock Group is engaged in global diversified investments.
|
Locked | Locked | Locked |
Investor details for Tango Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tango Therapeutics
Investment portfolio details for Tango Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Tango Therapeutics
Detailed financials for Tango Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tango Therapeutics Comparisons
Peer comparison for Tango Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Tango Therapeutics
Tango Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Metabolon and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Solutions for biomarker discovery and diagnostic testing are provided.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Tango Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tango Therapeutics
Complete news archive for Tango Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tango Therapeutics
Tango Therapeutics was founded in 2017.
Tango Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Barbara Weber is the current CEO of Tango Therapeutics.
Tango Therapeutics is a funded company, having raised a total of $165M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Tango Therapeutics is 155.
Annual revenue of Tango Therapeutics is $42.07M as on Dec 31, 2024.
Tango Therapeutics was founded in 2017 in Cambridge, United States, as a biotechnology firm focused on oncology. Precision therapies are created by identifying genetic vulnerabilities in tumor suppressor genes through DNA sequencing and CRISPR-based functional screens. Targets are selected for specific patient subgroups, exploiting synthetic lethality to induce tumor cell death while sparing healthy cells. Operations center on early-stage drug discovery in the precision medicine sector.
Tango Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Tango Therapeutics offers PRMT5 Program and CoREST Program.
Yes, Tango Therapeutics is publicly traded on NASDAQ under the ticker symbol TNGX.
Tango Therapeutics has 5 investors. Key investors include Gilead, Casdin Capital, Boxer Capital, Tavistock Group, and Third Rock Ventures.
The ticker symbol of Tango Therapeutics is TNGX on NASDAQ.